Morningstar

Morningstar, Inc.

Equity Bottom-Up

Seattle Genetics reported revenue of $218 million, up 28% from last year. Adcetris sales of $159 million in the U.S. and Canada were up 30% from last year and 17% sequentially, which represents solid growth that helps offset the company's weaker first quarter. Adcetris, which is used to treat classical Hodgkin's lymphoma and anaplastic large cell lymphoma, remains the company's key driver, and we anticipate steady double-digit growth for the next several years due to Adcetris' solid efficacy and…

We think Seattle Genetics' next-generation cancer therapy Adcetris and robust pipeline, which are based on its proprietary antibody-drug conjugate, or ADC, technology platform, make it stand out among its emerging biotech peers. The firm's leading ADC technology has allowed it to develop an internal pipeline of innovative cancer treatments and become the partner of choice for leading oncology players. The technology improves the potency and safety of cancer-targeting monoclonal antibodies by…

Seattle Genetics reported revenue of $195 million, slightly below our expectations, with Adcetris sales seasonably softer in the first quarter. Net Adcetris sales of $135 million in the United States and Canada represent a 42% increase from last year, and we are maintaining our forecast of about $610 million for the full year, which falls at the lower end of management's maintained guidance. Operating expenses were mostly in line with our expectations, with costs and expenses from Seattle's…

United States

Seagen Inc. operates as a biotechnology company. The Company discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases, as well as offers antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. Seagen serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00